Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY23 results · Oct–Dec 2022
Astec LifeSciences reported revenue from operations of ₹117.18 crore (down 32.4% from Q3 FY22) and net profit of ₹0.85 crore (down 96.6% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 117.18 | 173.35 | −32.4% | 199.75 | −41.3% |
| Other income | 3.79 | 1.96 | +93.3% | 3.99 | −4.9% |
| Total income | 120.97 | 175.31 | −31.0% | 203.73 | −40.6% |
| Profit before tax | 1.24 | 33.21 | −96.3% | 24.58 | −95.0% |
| Net profit for the period | 0.85 | 24.75 | −96.6% | 18.31 | −95.4% |
| Attributable to shareholders of the company | 0.84 | 24.75 | −96.6% | 18.31 | −95.4% |
| EPS, basic (₹) | 0.43 | 12.63 | −96.6% | 9.34 | −95.4% |
| Net margin (%) | 0.7 | 14.3 | 9.2 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 117.18 | 173.35 | −32.4% | 199.75 | −41.3% |
| Other income | 3.78 | 1.96 | +92.9% | 3.98 | −5.0% |
| Total income | 120.96 | 175.31 | −31.0% | 203.73 | −40.6% |
| Profit before tax | 1.21 | 33.19 | −96.3% | 24.56 | −95.1% |
| Net profit for the period | 0.83 | 24.74 | −96.7% | 18.30 | −95.5% |
| EPS, basic (₹) | 0.42 | 12.63 | −96.7% | 9.34 | −95.5% |
| Net margin (%) | 0.7 | 14.3 | 9.2 |
Consolidated
- Filed with BSE
- 31 Jan 2023, 16:25 IST
- Board meeting
- 30 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2023, 16:25 IST
- Board meeting
- 30 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE